搜索
Search
img

News Center

新闻中心

Ms. Lu Yan Serves as Kintor's Chief Financial Officer

  • Time of issue:2019-12-13

(Summary description)[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls

Ms. Lu Yan Serves as Kintor's Chief Financial Officer

(Summary description)[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2019-12-13 14:22
  • Views:
Information
1[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls
Ms. Lu Yan has more than 13 years of experience in the capital markets industry. Before joining our Group, Ms. Lu served as head, director and general manager of the Overseas Investment Banking Department of the GF Securities, and was directly responsible for customer maintenance and project execution in China's healthcare industry. Prior to joining GF Securities in July 2018, Ms. Lu had worked for approximately 11 years in the Investment Banking Department of UBS AG Hong Kong office, and served as an executive director of the Asian Healthcare Team when she left the company. She has served as a signing Principal for Hong Kong sponsorship IPOs since 2014 and is well experienced in regulatory communication and implementation. Before joining UBS, Ms. Lu worked in the Asia Investment Bank department of Credit Suisse, focusing on serving Chinese customers. She was a leader in many capital market transactions in the health care industry, including restructuring and IPO issuance, secondary market issuance, existing stock placement, mergers and acquisitions and financing provision. Ms. Lu holds a master's degree in finance from the Guanghua School of Management, Peking University and a bachelor's degree in finance from the School of Finance, Renmin University of China. While studying at Peking University, she was selected as an exchange student to take MBA courses at the University of Chicago Booth School of Business (formerly: the Business School of University of Chicago).
Suzhou Kintor, established in 2009, is a company dedicated to the research and development of innovative drugs domestically and globally, focusing on the treatment of major cancers such as prostate cancer, breast cancer and liver cancer, as well as other diseases that lack effective therapy such as hair loss and acne. Besides, the Group has advanced a number of clinical studies to phase I - III stage. "Our Group extends a warm welcome to Ms. Lu Yan. She is well experienced in finance, capital markets and corporate finance, and has a keen insight into the biopharmaceutical industry. I believe her joining into our Group will enable our Group to better connect with the capital market and help achieve long-term strategic goals for novel drugs development”, said Dr. Youzhi Tong, Chairman and CEO of the Group.
About Suzhou Kintor and the Group
Founded in March 2009, Suzhou Kintor is an innovative enterprise and industrialized platform which is committed to the development of “best-in-class” and “first-in-class” drugs. The Group's products are all Class-1 novel drugs, which cover major cancers such as the prostate cancer, breast cancer, liver cancer, and hair loss and acne that are short of effective therapies. Many projects have been listed as the National Special Project for "Significant Novel Drugs Development" during the 12th and 13th Five-Year Plan period. Major product, Proxalutamide, is undergoing clinical trials in China and the United States concurrently. Clinical trials of this product are conducted as a second-line therapy and a first-line therapy for mCRPC in the phase III in China and in the phase II in the United States. Phase I/Ib clinical trials have been completed in China for metastatic breast cancer, and Phase Ic clinical trials for combined drugs are ongoing for HR+/AR+/HER2- breast cancer; Phase I clinical trials of KX-826 for androgenetic alopecia have been completed in China and the United States, and phase II clinical trials are ready to be carried out in China and the United States; ALK-1 monoclonal antibody is the first project to be granted global development rights for novel drugs against tumor by Pfizer to Chinese companies. Two phase I clinical trials in more than 100 subjects have been completed in the U.S. and other regions. A phase II clinical trials is currently being conducted in Taiwan for ALK-1 monoclonal antibody combined with PD-1 (Nivolumab) for the treatment of liver cancer. Our Group's other two projects include mTOR kinase-targeted inhibitors and HedgeHog / SMO inhibitors in clinical stage. The pre-clinical R&D pipelines also include AR-Degrader, c-Myc inhibitors and IDO inhibitors. Recently, Kintor has been rewarded the titles of the "Potential Unicorn Enterprise in the South Jiangsu National Independent Innovation Demonstration Zone", the "Unicorn Cultivation Enterprise in Suzhou City", the "Unicorn Enterprise in Suzhou Industrial Park", and the "Leading Major Innovation Team in Gusu", "Top 50 Potential Investment Enterprises in China" in 2019 from Chuangye Zone / Zero2IPO Group, "Outstanding Biopharma Enterprise Awards" in 2019 from China Finance (Hong Kong), and the "Top 50 Chinese Health Care Innovation Enterprises” in 2019 from Chuangye Zone.

Scan the QR code to read on your phone

News Center

Company News    Media Reports

Contact Us

Find Us

这是描述信息